180 related articles for article (PubMed ID: 26279632)
1. Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia.
Yassin MA; Moustafa AH; Nashwan AJ; Soliman AT; El Derhoubi H; Mohamed SF; Mudawi DS; ELkourashy S; Asaari DR; Gutierrez HL; Hussein RM; Al Musharraf M; Kohla S; Elsayed A; Al-Dewik N
Clin Med Insights Blood Disord; 2015; 8():19-23. PubMed ID: 26279632
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. Avascular necrosis in patients with chronic myeloid leukemia: A systematic review.
Yassin M; Al-Mashdali AF; Al-Dubai HN
Acta Biomed; 2022 Mar; 93(1):e2022017. PubMed ID: 35315390
[TBL] [Abstract][Full Text] [Related]
4. Nilotinib induced avascular necrosis of femoral head in an adult chronic myeloid leukemia patient.
Thekkudan SF; Nityanand S
J Clin Orthop Trauma; 2018 Jun; 9(Suppl 2):S26-S28. PubMed ID: 29928099
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
[TBL] [Abstract][Full Text] [Related]
6. Targeted drugs in chronic myeloid leukemia.
Gora-Tybor J; Robak T
Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
[TBL] [Abstract][Full Text] [Related]
7. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
10. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
11. A unique three-way Philadelphia chromosome variant t(4;9;22)(q21;q34;q11.2) in a newly diagnosed patient with chronic phase chronic myeloid leukemia: a case report and review of the literature.
Torii Y; Nanjo K; Toubai T; Hosokawa M; Sato R; Yamada A; Aizawa K; Himuro M; Ito S; Yamamoto M; Magenau J; Wilcox R; Ishizawa K
J Med Case Rep; 2021 May; 15(1):285. PubMed ID: 34030730
[TBL] [Abstract][Full Text] [Related]
12. A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia.
Ciftciler R; Saglam EA; Inanc A; Ozcebe O; Haznedaroglu IC
Cancer Genet; 2019 Sep; 237():78-81. PubMed ID: 31447069
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.
Leonetti F; Stefanachi A; Nicolotti O; Catto M; Pisani L; Cellamare S; Carotti A
Curr Med Chem; 2011; 18(19):2943-59. PubMed ID: 21651486
[TBL] [Abstract][Full Text] [Related]
14. Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
Mace ML; Dahl J; Jabbour EJ
Expert Opin Pharmacother; 2015 May; 16(7):999-1007. PubMed ID: 25840461
[TBL] [Abstract][Full Text] [Related]
15. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
Tabarestani S; Movafagh A
Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
17. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
18. A case of avascular necrosis of the femoral head as initial presentation of chronic myelogenous leukemia.
Moon JY; Kim BS; Yun HR; Choi JH; Lee YY; Kim IS; Ahn MJ
Korean J Intern Med; 2005 Sep; 20(3):255-9. PubMed ID: 16295787
[TBL] [Abstract][Full Text] [Related]
19. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
Qing X; Qing A; Ji P; French SW; Mason H
Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
[TBL] [Abstract][Full Text] [Related]
20. Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients.
Bennour A; Bellâaj H; Ben Youssef Y; Elloumi M; Khelif A; Saad A; Sennana H
J Cancer Res Clin Oncol; 2011 Sep; 137(9):1329-36. PubMed ID: 21739181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
